Dose ranging study of cefpimizole (U-63196E) for treatment of uncomplicated gonorrhea in men. 1986

E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook

We conducted a two-center dose ranging study to evaluate the efficacy, tolerance, and toxicity of cefpimizole, a new cephalosporin, in the treatment of uncomplicated gonorrhea in 96 males. Twelve patients at each center were treated intramuscularly with single doses of 1.0, 0.5, 0.25, and 0.125 g of cefpimizole. All urethral infections were cured at the highest dose, but lower doses produced progressively decreasing cure rates of 90% (0.5 g), 83% (0.25 g), and 71% (0.125 g). Treatment failures of rectal and pharyngeal infections occurred at the highest dose level. Geometric mean MICs for cefpimizole for successfully and unsuccessfully treated volunteers were 0.088 and 0.282 micrograms/ml, respectively. A prominent adverse effect was clinically significant pain at the injection site, which occurred in 57 (59%) of 96 patients. Results of the study demonstrate that cefpimizole offers no advantage over currently available antibiotics in the treatment of uncomplicated gonorrhea in men.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009344 Neisseria gonorrhoeae A species of gram-negative, aerobic bacteria primarily found in purulent venereal discharges. It is the causative agent of GONORRHEA. Diplococcus gonorrhoeae,Gonococcus,Gonococcus neisseri,Merismopedia gonorrhoeae,Micrococcus der gonorrhoe,Micrococcus gonococcus,Micrococcus gonorrhoeae
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D006069 Gonorrhea Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879. Neisseria gonorrhoeae Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
December 1981, Antimicrobial agents and chemotherapy,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
July 1996, Antimicrobial agents and chemotherapy,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
July 1985, Antimicrobial agents and chemotherapy,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
January 1988, Sexually transmitted diseases,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
January 1983, Sexually transmitted diseases,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
August 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
January 1986, Chemotherapy,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
January 1984, Sexually transmitted diseases,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
October 1986, Antimicrobial agents and chemotherapy,
E T Sandberg, and P S Pegram, and R E Roddy, and H H Handsfield, and K D Hampton, and K M Shafran, and E W Hook
October 1973, The Journal of infectious diseases,
Copied contents to your clipboard!